For the quarter ending 2026-03-31, EVFM made $899K in revenue. -$5,485K in net income. Net profit margin of -610.12%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Product sales, net | 899 | 9,561 | 4,952 | 4,825 |
| Cost of goods sold | 410 | 2,592 | 905 | 755 |
| Amortization of intangible asset | - | - | - | 107 |
| Loss on change in accounting estimates on contingent royalty liability (note 7) | - | -3,866* | 1,933 | - |
| Amortization of intangible asset | 75 | 96 | 80 | 100 |
| Research and development, net | 518 | -3,501* | 470 | 746 |
| Selling and marketing | 2,093 | 2,066 | 2,391 | 2,625 |
| General and administrative | 2,372 | 1,097 | 2,088 | 1,843 |
| Total operating expenses | 5,468 | 6,216 | 4,001 | 6,076 |
| Income (loss) from operations | -4,569 | 3,345 | 951 | -1,251 |
| Interest income | 2 | 2 | 3 | 2 |
| Gain on debt extinguishment, net | - | - | - | 0 |
| Loss on issuance of financial instruments | - | - | - | 0 |
| Other expense, net | 737 | 691 | 682 | 662 |
| Change in fair value of financial instruments | -162 | 131 | -1,845 | 134 |
| Total other income (expense), net | -897 | -558 | -2,524 | -526 |
| Income (loss) before income tax expense | -5,466 | 2,787 | -1,573 | -1,777 |
| Income tax expense | -1 | -1 | -4 | 7 |
| Net income (loss) | -5,465 | 2,788 | -1,569 | -1,784 |
| Convertible and redeemable preferred stock deemed dividends | 20 | 2 | 111 | -1 |
| Net income (loss) attributable to common stockholders | -5,485 | 2,786 | -1,680 | -1,785 |
| Basic EPS | -0.04 | 0.019 | -0.01 | -0.02 |
| Diluted EPS | -0.04 | 0 | -0.01 | -0.02 |
| Basic Average Shares | 133,246,864 | 146,011,189 | 119,578,093 | 115,686,024 |
| Diluted Average Shares | 133,246,864 | 6,421,746,555* | 119,578,093 | 115,686,024 |
Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)